NCT03943667已完成3 期
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- UNICANCER
- 入组人数
- 211
- 试验地点
- 26
- 主要终点
- Overall Survival
研究概览
简要总结
This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after FOLFIRINOX failure or intolerance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic Pancreatic Ductal Adenocarcinoma with histological or cytological proof
- •Age ≥18 years
- •At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 outside any previously irradiated area
- •Failure of first line FOLFIRINOX (Progressive disease during therapy of within 3 months +/- 15 days)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2
- •Life expectancy ≥12 weeks
- •Negative serology (HIV, hepatitis B and C)
- •Adequate organs function
- •Proven Post-menopausal status or negative urinary or serum pregnancy test
- •Woman of childbearing potential and male patients must agree to use adequate contraception fo the duration of the trial and up to 6 months after completing treatment
- •Patients affiliated to the social security system
- •Patient must have signed a written informed consent form
排除标准
- •Any other primary tumor or secondary malignancy except basal cell carcinoma of skin or in situ carcinoma of the cervix uteri
- •Known cerebral metastasis
- •Uncontrolled severe infections
- •Patients with Kaposi's sarcoma
- •Peripheral neuropathy exceeding grade 2 on Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- •Previous treatment with taxane and/or gemcitabine (for pancreas cancer only)
- •Patients with known allergy or severe hypersensitivity to any trial drug or drug excipient
- •Patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment
- •Patients unable to comply with trial obligations for geographic, social or physical reasons, or who are unable to understand the purpose and procedures of the trial
- •Participation in another clinical trial within 14 days prior to randomization
- •Patients deprived of liberty or under legal protection measures or patients whose willingness to participate in the trial may be unduly influenced
研究组 & 干预措施
GEMPAX
Experimental
Gemcitabine + Paclitaxel until progression
干预措施: Gemcitabine (Drug)
GEMPAX
Experimental
Gemcitabine + Paclitaxel until progression
干预措施: Paclitaxel (Drug)
Control
Active Comparator
Gemcitabine alone until progression
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Overall Survival
时间窗: Until death (life expectancy around 12 months)
Time from the date of randomization to the date of death from any cause
次要结局
未报告次要终点
研究者
研究点 (26)
Loading locations...
相似试验
已完成
2 期
Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast CancerMetastatic Breast CancerNCT00316199Eli Lilly and Company60
终止
3 期
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by SurgeryStage I Uterine Sarcoma AJCC v7Uterine Corpus LeiomyosarcomaNCT01533207Gynecologic Oncology Group38
已完成
2 期
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st LineBreast CancerNCT00191854Eli Lilly and Company147
已完成
3 期
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Distal Bile Duct Cancer AJCC v8Stage IIIA Gallbladder Cancer AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Distal Bile Duct Cancer AJCC v8Stage IIIB Gallbladder Cancer AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Stage IVA Gallbladder Cancer AJCC v8Stage IVB Gallbladder Cancer AJCC v8Unresectable Extrahepatic Bile Duct CarcinomaUnresectable Gallbladder CarcinomaUnresectable Intrahepatic CholangiocarcinomaNCT03768414SWOG Cancer Research Network452
已完成
1 期
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic CancerAdenocarcinomaPancreatic NeoplasmsNeoplasm, GlandularNeoplasmsNeoplasms PancreaticEndocrine Gland NeoplasmsDigestive System DiseasePancreatic DiseasesEndocrine System DiseasesDigestive System NeoplasmNCT03535727Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins48